Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
CONTEXT: Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells. These mechanisms may explain the effectiveness of IVIG in autoimmune neuromuscular disorders. OBJECTIVE: To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials. DATA SOURCES: Peer-reviewed publications identified through MEDLINE (1966-2003), EMBASE (1974-2003), and references from bibliographies of pertinent articles. Each autoimmune neuromuscular disease term was searched in combination with the term intravenous immunoglobulin. STUDY SELECTION AND DATA EXTRACTION: Criteria for selection of studies included controlled study design, English language, and clinical pertinence. Data quality was based on venue of publication and relevance to clinical care. DATA SYNTHESIS: Outcomes of controlled trials indicate that IVIG at a total dose of 2 g/kg is effective as first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton myasthenic syndrome. In other controlled studies, IVIG produced a modest, variable, and transient but not statistically significant benefit in patients with inclusion body myositis and paraproteinemic anti-myelin-associated glycoprotein antibody demyelinating polyneuropathy. Intravenous immunoglobulin is not effective in patients with multiple sclerosis who have established weakness or optic neuritis. In myasthenia gravis, it should be reserved for difficult cases or before thymectomy in lieu of plasma exchange. CONCLUSION: Intravenous immunoglobulin is effective in many autoimmune neurologic diseases, but its spectrum of efficacy, especially as first-line therapy, and the appropriate dose for long-term maintenance therapy are not fully established. Further controlled studies of IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are warranted to improve the evidence base for clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667 · cited 1×
“5 mi l l ion Americans and cause significant morbidity and disability.(1) Neurologic disorders represent about half of the diseases for which there is evidence of autoimmune pathogenesis.”
BackgroundDelves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Self-citationPolymyositis and Dermatomyositis
Hohlfeld, R., Hofmann, W. W., & Hanley, D. F. (1994) · Neurocritical Care · doi:10.1007/978-3-642-87602-8_72 · Cited by 1,083
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Polymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J., Wedderburn, L. R., & Hanna, M. G. (2013) · UCL Discovery (University College London) · Cited by 764
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
Self-citation(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Acute motor axonal neuropathy: An antibody‐mediated attack on axolemma
Hafer‐Macko, C., Hsieh, S., Ho, T. W., Sheikh, K., Cornblath, D. R., Li, C. Y., McKhann, G. M., Asbury, A. K., & Griffin, J. W. (1996) · Annals of Neurology · doi:10.1002/ana.410400414 · Cited by 512
Dyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360607 · Cited by 471
Hahn, A. F., Bolton, C. F., Zochodne, D., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1067 · Cited by 439
High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome
Dalakas, M. C., Fujii, M., Li, M., Lutfi, B., Kyhos, J., & McElroy, B. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa01167 · Cited by 434
Self-citationClinical spectrum of chronic acquired demyelinating polyneuropathies
Saperstein, D. S., Katz, J. S., Amato, A. A., & Barohn, R. J. (2001) · Muscle & Nerve · doi:10.1002/1097-4598(200103)24:3<311::aid-mus1001>3.0.co;2-a · Cited by 417
Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy
Hafer‐Macko, C. E., Sheikh, K. A., Li, C. Y., Ho, T. W., Cornblath, D. R., McKhann, G. M., Asbury, A. K., & Griffin, J. W. (1996) · Annals of Neurology · doi:10.1002/ana.410390512 · Cited by 416
Pathogenesis of Guillain–Barré syndrome
Hughes, R. A. C., Hadden, R. D. M., Gregson, N. A., & Smith, K. J. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00195-2 · Cited by 405
Basta, M., & Dalakas, M. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117520 · Cited by 396
Self-citationHahn, A. F. (1998) · The Lancet · doi:10.1016/s0140-6736(97)12308-x · Cited by 395
Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., & Mamoli, B. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09377-4 · Cited by 381
Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
Dalakas, M. C., Sonies, B., Dambrosia, J., Sekul, E., Cupler, E., & Sivakumar, K. (1997) · Neurology · doi:10.1212/wnl.48.3.712 · Cited by 350
Self-citationThe clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome
Dalakas, M. C., Fujii, M., Li, M., & McElroy, B. (2000) · Neurology · doi:10.1212/wnl.55.10.1531 · Cited by 331
Self-citationInfectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes
Yuki, N. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00019-6 · Cited by 326
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1447 · Cited by 306
Nobile‐Orazio, E., Manfredini, E., Carpo, M., Meucci, N., Monaco, S., Ferrari, S., Bonetti, B., Cavaletti, G., Gemignani, F., Durelli, L., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410360313 · Cited by 277
Dalakas, M. C. (1994) · Neurology · doi:10.1212/wnl.44.2.223 · Cited by 274
Self-citationMultifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study
Federico, P., Zochodne, D. W., Hahn, A. F., Brown, W. F., & Feasby, T. E. (2000) · Neurology · doi:10.1212/wnl.55.9.1256 · Cited by 263
Bain, P. G., Motomura, M., Newsom-Davis, J., Misbah, S. A., Chapel, H. M., Lee, M. L., Vincent, A., & Lang, B. (1996) · Neurology · doi:10.1212/wnl.47.3.678 · Cited by 261
Van den Berg, L. H., Kerkhoff, H., Oey, P. L., Franssen, H., Mollee, I., Vermeulen, M., Jennekens, F. G., & Wokke, J. H. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.3.248 · Cited by 254
Walter, M. C., Lochmüller, H., Toepfer, M., Schlotter, B., Reilich, P., Schröder, M., Müller-Felber, W., & Pongratz, D. (2000) · Journal of Neurology · doi:10.1007/s004150050005 · Cited by 235
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
Dalakas, M. C., Koffman, B., Fujii, M., Spector, S., Sivakumar, K., & Cupler, E. (2001) · Neurology · doi:10.1212/wnl.56.3.323 · Cited by 233
Self-citationDemyelinating Neuropathy in Diabetes Mellitus
Sharma, K. R. (2002) · Archives of Neurology · doi:10.1001/archneur.59.5.758 · Cited by 202
Ho, T. W., Hsieh, S.-T., Nachamkin, I., Willison, H. J., Sheikh, K., Kiehlbauch, J., Flanigan, K., McArthur, J. C., Cornblath, D. R., McKhann, G. M., et al. (1997) · Neurology · doi:10.1212/wnl.48.3.717 · Cited by 187
INSERM (2020) · Definitions · doi:10.32388/81w39q · Cited by 179
Dalakas, M. C. (2002) · Neurology · doi:10.1212/wnl.59.12_suppl_6.s13 · Cited by 171
Self-citationVan den Berg‐Vos, R. M., Franssen, H., Wokke, J. H. J., & Berg, L. H. V. D. (2002) · Brain · doi:10.1093/brain/awf193 · Cited by 168
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Noseworthy, J. H., O’Brien, P. C., Petterson, T. M., Weis, J., Stevens, L., Peterson, W. K., Sneve, D., Cross, S. A., Leavitt, J. A., Auger, R. G., et al. (2001) · Neurology · doi:10.1212/wnl.56.11.1514 · Cited by 163
Comı, G., Roveri, L., Swan, A., Willison, H. J., Bojar, M., Illa, I., Karageorgiou, C. E., Nobile‐Orazio, E., den Bergh, P. V., Swan, T., et al. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0808-z · Cited by 157
The distribution of ganglioside-like moieties in peripheral nerves
Sheikh, K. A., Deerinck, T. J., Ellisman, M. H., & Griffin, J. W. (1999) · Brain · doi:10.1093/brain/122.3.449 · Cited by 145
Intravenous immunoglobulins neutralize blocking antibodies in Guillain‐Barré syndrome
Buchwald, B., Ahangari, R., Weishaupt, A., & Toyka, K. V. (2002) · Annals of Neurology · doi:10.1002/ana.10205 · Cited by 144
The clinical correlates of high‐titer IgG anti‐GM1 antibodies
Kornberg, A. J., Pestronk, A., Bieser, K., Ho, T. W., McKhann, G. M., Wu, H. S., & Jiang, Z. (1994) · Annals of Neurology · doi:10.1002/ana.410350217 · Cited by 135
Intravenous immunoglobulin for dysphagia of inclusion body myositis
Cherin, P., Pelletier, S., Teixeira, A., Laforêt, P., Simon, A., Herson, S., & Eymard, B. (2002) · Neurology · doi:10.1212/wnl.58.2.326 · Cited by 122
Marchioni, E., Marinou, K., Uggetti, C., Bottanelli, M., Pichiecchio, A., Soragna, D., Piccolo, G., Imbesi, F., Romani, A., & Ceroni, M. (2002) · Journal of Neurology · doi:10.1007/pl00007836 · Cited by 114
Molecular Immunology and Genetics of Inflammatory Muscle Diseases
Dalakas, M. C. (1998) · Archives of Neurology · doi:10.1001/archneur.55.12.1509 · Cited by 113
Self-citationNoseworthy, J. H., O’Brien, P. C., Weinshenker, B. G., Weis, J. A., Petterson, T. M., Erickson, B. J., Windebank, A. J., Whisnant, J., Stolp‐Smith, K. A., Harper, C. M., et al. (2000) · Neurology · doi:10.1212/wnl.55.8.1135 · Cited by 105
Strokes, thromboembolic events, and IVIg
Dalakas, M. C., & Clark, W. M. (2003) · Neurology · doi:10.1212/01.wnl.0000074394.15882.83 · Cited by 94
Self-citationImmune mechanisms in chronic inflammatory demyelinating neuropathy
Kieseier, B. C., Dalakas, M. C., & Hartung, H. (2002) · Neurology · doi:10.1212/wnl.59.12_suppl_6.s7 · Cited by 86
Self-citationDalakas, M. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370703 · Cited by 78
Self-citationMolecular mimicry between non-self, modified self and self in autoimmunity
Karlsen, A. E., & Dyrberg, T. (1998) · Seminars in Immunology · doi:10.1006/smim.1997.0102 · Cited by 76
The molecular and cellular pathology of inflammatory muscle diseases
Dalakas, M. C. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00053-4 · Cited by 61
Self-citationIntravenous γ‐globulin inhibits binding of anti‐GM1 to its taget antigen
Malik, U. R., Oleksowicz, L., Larov, N., & Cardo, L. J. (1996) · Annals of Neurology · doi:10.1002/ana.410390121 · Cited by 56
Dalakas, M. C., Stein, D. P., Otero, C., Sekul, E. A., Cupler, E., & McCrosky, S. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210031010 · Cited by 56
Self-citationImmunotherapy in autoimmune neuromuscular disorders
Gold, R., Dalakas, M. C., & Toyka, K. V. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00264-3 · Cited by 55
Self-citationBašta, M., Illa, I., & Dalakas, M. C. (1996) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00133-6 · Cited by 53
Self-citation
Cited by
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
How citation distortions create unfounded authority: analysis of a citation network
Greenberg, S. A. (2009) · BMJ · doi:10.1136/bmj.b2680 · Cited by 499
Immunotherapy for Guillain-Barre syndrome: a systematic review
Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., & van Doorn, P. A. (2007) · Brain · doi:10.1093/brain/awm004 · Cited by 463
Metadata
- Authors
- Dalakas, M. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-19
- Volume
- 291
- Issue
- 19
- Pages
- 2367
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1975756380
- Cited by
- 329
- References
- 56
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.